DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) was founded to develop and commercialize new cancer therapies in indications where patients are failing or have become intolerable to modern targeted or biologic treatments, according to the company’s website (see here: www.DelMarPharma.com). SNNLive caught up with Jeffrey Bacha, Chairman & CEO of DelMar Pharmaceuticals, Inc. at the 2016 Aegis Growth Conference in Las Vegas, NV.
In this video interview, Mr. Bacha and our host discuss the following topics:
- Overview of DelMar Pharmaceuticals, Inc.
- Discusses recent news
- Company’s therapies
- Clinical developments
- Goals and milestones for rest of 2016-2017
- Orphan drug designation
For more information about DelMar Pharmaceuticals, Inc., please visit: www.DelMarPharma.com
The interview may contain forward-looking statements about DelMar Pharmaceuticals, Inc. See DelMar's periodic filings with the Securities and Exchange Commission for more complete information.
© 2017 Stock News Now
Supported by Superior Web Solutions